Global protease inhibitor market, on the basis of geography, is segmented into Asia Pacific, Latin America, Europe, North America and Middle East & Africa. Protease inhibitors (PIs) are a class of antiviral drugs that are widely used to treat HIV/AIDS and hepatitis C. Protease inhibitors prevent viral replication selectively binding to viral proteases and blocking proteolytic cleavage of protein precursors that are necessary for the production of infectious viral particles. Protease inhibitors bind to the active site of the protease enzyme and prevent the maturation of the newly produced virions so that they remain non-infectious. Protease inhibitors are used in the treatment of human immunodeficiency virus (HIV infection) and acquired immune deficiency syndrome (AIDS). In addition, there are many more proteases found in viruses, bacteria and parasites which are also potential drug targets.
View Full Report with TOC @ https://www.millioninsights.com/industry-reports/protease-inhibitor-pi-market
Factors such as rising incidences of HIV, Aids and immune-related problems propelled the market growth in the predicted period. Also, the rise in medical infrastructure and rise in diagnostic measures also contributed to the market growth. Proteases comprise drug targets for HIV and the clotting cascade as well as degradative enzymes such as elastase and dipeptidyl peptidases such as DPP IV. Many viral, bacterial and parasitic proteases are also potential drug targets and due to their lower homology to their mammalian orthologs, offer target opportunities to identify selective inhibitors that have minimal cross-reactivity with mammalian proteases.
Geographically, the global protease inhibitor market spans North America, Latin America, Europe, Asia-Pacific, Middle-East & Africa. North America dominated the global market owing to rising prevalence of AIDS and immune-related problems. APAC market also anticipated in significant growth in the global market owing The key players in the protease inhibitor market include CSL Ltd., Grifols S.A, Baxalta Incorporated, Octapharma AG, KedrionS.p.A, China Biologic Products Inc., Biotest AG, LFB S.A, Bio Product Laboratory Ltd. and Sanquin.
Request a Sample Copy of This Report @ https://www.millioninsights.com/industry-reports/protease-inhibitor-pi-market/request-sample
No comments:
Post a Comment